Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patientsThe detection of RAS mutations and co-mutations in liquid biopsy offers a novel paradigm for the dynamic management of metastatic colorectal cancer (mCRC) patients. ...
The phosphoinositide 3-kinase (PI3K)–Akt axis is one of the most frequently activated pathways and is demonstrated as a therapeutic target in Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated colorectal cancer (CRC). Targeting the PI3K–Akt pathway has been a challenging undertaking through...
The treatment of metastatic colon cancer depends, in part, on KRAS mutation status. Colon cancers that are wild-type KRAS can be treated with monoclonal antibodies such as cetuximab and panitumumab against the epidermal growth factor receptor (EGFR), and a proportion of individuals will have ...
RECTAL cancerMetastatic colon cancer remains an incurable disease, and it is difficult for existing treatments to achieve the desired clinical outcome, especially for colon cancer patients who have received first-line treatment. Although immune checkpoint inhibitors (ICIs) have...
COLON cancerA study published in Cancer Discovery suggests that patients with KRASG12C-mutated colorectal cancer (CRC) may have a new potential treatment option. The study found that a combination of adagrasib and cetuximab showed promising clinical activity and tolerable safety in treating this ...
IRINOTECANCOLON cancer treatmentTHERAPEUTICSA response from the author of the article "V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer" in the November 15, 2013 issue is presented....
Researchers from the Massachusetts General Hospital (MGH) Cancer Center have identified a new potential strategy for treating colon tumors driven by mutations in the KRAS gene, which usually resist both conventional and targeted treatments. In a paper appearing in the Feb. 17 issue of Cell, the ...
The method comprises administering to the subject an effective amount of an antibody or antigen binding fragment thereof wherein the antibody or antigen binding fragment thereof competes with SC104 for binding to the human colon cancer cell line Colo205.Kienzle, Norbert A...
Tumor growth was significantly suppressed with PBR extract and cetuximab co-treatment. In conclusion, PBR increased the sensitivity of KRAS-mutated colon cancer cells to cetuximab, which indicates the potential use of PBR as a medical food against colon cancer.Park, Hye-JinPark, Jeong-BinLee, ...
The present invention provides a method of treating cancer in a subject, wherein the cancer comprises a mutated KRAS or BRAF gene. 本方法包括向受试者施用有效量的抗体或其抗原结合片段,其中抗体或其抗原结合片段与SC104竞争来结合至人结肠癌细胞系Colo205. The method comprises administering to the ...